MedTrace Logo

Brain Imaging Studies of the Effect of Inhalant Use Disorder

NCT02188914 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2017-08-17

No results posted yet for this study

Summary

Inhalants substance misuse is an important public health problem whose prevalence is approximately 1% in the general population and 7% among high school students in Mexico. Furthermore Inhalants substance misuse has increased in the recent years (Villatoro et al., 2011). According to the Diagnostic and Statistical Manual of Mental Disorders fifth edition (DSM-5) inhalant use disorder is a problematic pattern of use of a hydrocarbon-based inhalant substance leading to clinically significant impairment or distress. There are studies to suggest that long-term exposure to inhalants is associated with structural brain abnormalities, as well as neuropsychological impairments. However many of these studies have been limited to the gross anatomical report, therefore is necessary the use of complimentary techniques which provide a better understanding of brain. To the date there is no evidence of the use of positron emission tomography, and there are few studies have employed other magnetic resonance imaging methodologies such as diffusion tensor imaging that can be used to know the metabolic activity and white matter tract integrity respectively in inhalant use disorder participants. The purpose of this study is evaluates the effects of the inhalant use disorder in the brain. The investigators will be using positron emission tomography (PET), Magnetic Resonance Imaging (MRI) and diffusion tensor imaging (DTI). As well as, this study will examine the impact of inhalants consumption on executive function performance and the transcriptomic changes associated with inhalants consumption. The investigators hope that the data gathered from this study will lead to the development of more effective treatments

Conditions

  • Inhalant Use Disorder

Interventions

RADIATION

Positron emission tomography scan

OTHER

Magnetic resonance imaging

Sponsors & Collaborators

  • National Institute of Neurology and Neurosurgery, Mexico

    collaborator OTHER

  • Miguel Ángel Mendoza Meléndez

    lead OTHER_GOV

Principal Investigators

  • Miguel Ángel Mendoza Meléndez, MD, MPH · Institute for Attention and Prevention of Addictions in Mexico City

  • Nora Estela Kerik Rotenberg, MD · National Institute of Neurology and Neurosurgery Manuel Velasco Suárez.

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-11-01
Primary Completion
2016-07-30
Completion
2016-07-30

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02188914 on ClinicalTrials.gov